Drug Profile


Alternative Names: BAY-864875; Gadavist; Gadobutrol injection for MRI of CNS - Bayer; Gadovist; Gadovist 1.0; Gd-DO3A-butriol; SHL 562

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Gadolinium-containing contrast agents; Organometallic compounds; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Vascular disorders
  • Clinical Phase Unknown Brain cancer

Most Recent Events

  • 10 Aug 2017 Bayer completes the phase III GadaCAD 1 trial for Vascular disorders (diagnosis of coronary artery disease) in France, Germany, South Korea, New Zealand, Switzerland, United Kingdom and USA (NCT01890421)
  • 01 Apr 2017 Clinical trials in Brain cancer (Diagnosis) in Japan (IV)
  • 04 Jan 2017 Launched for Vascular disorders (Diagnosis) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top